0001193125-26-226608
SEC filingEHang faced revenue contraction and wider losses in FY2025 as EH216 series sales volumes declined in line with reduced cost of revenues, while operating losses deepened due to lower government subsidies and increased capital investments in production facilities.
Cash generation reversed sharply, with net cash used in operating activities at -$179.5 million versus $158.0 million provided in 2024, contributing to free cash flow of -$327.4 million. This shift coincided with capital expenditures rising to $147.9 million from $39.0 million, directed toward production facilities like the Yunfu site (300-unit annual Phase I capacity since 2021) to support future scaling. Management notes plans to fund ongoing capex from existing cash balances, while regulatory hurdles continue to cloud eVTOL commercialization timelines across key jurisdictions, prolonging the path to sustained volume growth and positive cash flows.
Overall, FY2025 highlights the challenges of transitioning from certification milestones to commercial operations, with sales volume sensitivity evident in aligned revenue and cost trends. Investors should monitor subsidy recognition, regulatory progress, and capex efficiency as EHang positions for potential rebound.